McKesson Specialty certified to launch Revlimid
McKesson Specialty, a subsidiary of McKesson Corp., has been certified by Celgene Corp. as one of a select group of RevAssist Program contract pharmacies to launch Revlimid (lenalidomide). To reduce fetal exposure to the drug, Revlimid is available only through RevAssist, a distribution network employing only certified, contracted specialty pharmacies.
McKesson Specialty certified to launch Revlimid
McKesson Specialty, a subsidiary of McKesson Corp., has been certified by Celgene Corp. as one of a select group of RevAssist Program contract pharmacies to launch Revlimid (lenalidomide). To reduce fetal exposure to the drug, Revlimid is available only through RevAssist, a distribution network employing only certified, contracted specialty pharmacies. Revlimid is an oral medication for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1 risk myelodysplastic syndromes (MDS) associated with a missing part of chromosome 5 (known as deletion 5q MDS).
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
